This is an attainable goal. The genomic search space is large but finite and so, in theory, elucidating the parts list for a psychiatric disorder could be achieved. Based on the evidence to date, thorough and well-powered genomic evaluations across the allelic spectrum are needed. We believe that a balanced portfolio of genomic assessments is required, as there are clear roles for common variation, SV, rare variation, and de novo variation for most disorders. Most discoveries in psychiatric genetics to date are from GWAS and SV evaluation (both often based on the use of GWAS chips), and larger and more comprehensive GWAS and SV studies are highly likely to increase knowledge. 135 It is possible to provide realistic estimates of power and to predict the number of new associations for each increment in sample size 128,129,140 (e.g., predictions have been made for GWAS and SV in 50,000 SCZ cases and 50,000 controls 140 ). Based on the recent ASD studies, sequencing directed at rare and de novo variation will have a role in a balanced portfolio of approaches. 83–85 Indeed,
